OpT2mise Glucose Control in Type 2 Diabetes Mellitus (DM) With Insulin Pump Therapy

This study is currently recruiting participants.
Verified April 2013 by Medtronic
Information provided by (Responsible Party):
ClinicalTrials.gov Identifier:
First received: August 11, 2010
Last updated: April 12, 2013
Last verified: April 2013

The purpose of this study is to evaluate the comparative effectiveness of insulin pump therapy versus multiple daily injections in insulin-taking type 2 Diabetes Mellitus who are sub optimally controlled with multiple daily injections (MDI).

Condition Intervention Phase
Diabetes Mellitus, Type 2
Device: Insulin Pump (Medtronic Minimed Paradigm® VEO)
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: OpT2mise Glucose Control in Type 2 DM With Insulin Pump Therapy

Resource links provided by NLM:

Further study details as provided by Medtronic:

Primary Outcome Measures:
  • Between group difference in HbA1c when comparing CSII to MDI [ Time Frame: 6 months ] [ Designated as safety issue: No ]
    To evaluate change in glycemic control (HbA1c) after 6 months of insulin pump therapy in patients with type 2 DM, as compared to patients on MDI therapy over the same time period

Secondary Outcome Measures:
  • Change in glycemic variability [ Time Frame: 6 months ] [ Designated as safety issue: No ]
    Glycemic parameters calculated from blinded CGM data: Measure of the Average glucose/day; AUC in hypo- (≤70mg/dL) and in hyperglycemia (≥180 mg/dL; Time spent in hypo- (≤70mg/dL) and hyperglycemia (≥180 mg/dL); Mean Amplitude of Glycemic Excursions (MAGE) is the most common measure of the volatility of blood glucose levels; Standard deviation

  • Safety [ Time Frame: 6 months treatment and 6 months follow-up ] [ Designated as safety issue: Yes ]
    Severe hypoglycemia incidence; Diabetic Ketoacidosis incidence and Diabetes related hospitalizations

  • Change in postprandial glycemia [ Time Frame: 6 months ] [ Designated as safety issue: No ]
    Change in mean postprandial hyperglycemia 0 to 2 hours post meal, defined as ≥180 mg/dl and measured by SMBG

  • Quality of Life and Treatment satisfaction [ Time Frame: 6 months ] [ Designated as safety issue: No ]
  • Change in body weight or BMI, Lipids and blood pressure [ Time Frame: 6 months ] [ Designated as safety issue: No ]

Estimated Enrollment: 400
Study Start Date: December 2010
Estimated Study Completion Date: September 2014
Estimated Primary Completion Date: January 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Insulin Pump Treatment
Patients will get an insulin pump
Device: Insulin Pump (Medtronic Minimed Paradigm® VEO)
The pump delivers insulin as specified by the patient
Other Name: Medtronic MiniMed Paradigm® VEO system (MMT-554/754
No Intervention: Insulin treatment with MDI
patients treated with Multiple Daily Injections (MDI); basal/bolus therapy with rapid- and long-acting analogs with at least 3 injections per day

Detailed Description:

The type of study is interventional post-market release. All the devices under investigation have CE mark, and are used within intended use.

This study has been designed to be prospective randomized controlled with a single-arm cross-over in the continuation phase.

Four hundred type 2 Multiple Daily Injections (MDI) treated patients will undergo a screening (run-in) phase of 8 weeks. The aim of the screening phase is to eliminate the study effect that might result in a decrease of HbA1c and to make sure that patients, who are failing current MDI therapy, are selected.

After this screening phase, eligible patients will be randomised to receive either Continuous Subcutaneous Insulin Infusion (CSII) treatment or continue MDI treatment. The first 6-months phase (2-arms parallel) will be followed by another 6-months continuation phase (single cross-over of the MDI arm alone switching to CSII).


Ages Eligible for Study:   30 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria at screening:

  1. Diagnosed with type 2 DM, as per Investigator discretion
  2. HbA1c (DCCT-standard) must be ≥ 8.0% and ≤12% as evidenced by central lab value taken at screening
  3. Insulin resistance defined as required daily dose between 0.5-1.8 U/Kg or a maximum of 220 units of insulin per day
  4. Aged 30 to 75 years old (inclusive)
  5. On MDI regimen (basal/bolus regimen with long-acting insulin and rapid acting analogs) defined as ≥ 3 injections per day for at least 3 months prior signing the informed consent
  6. Ability to comply with technology, according to Investigator's judgment
  7. Patients must be willing to undergo all study procedures
  8. Female patients of child-bearing potential must be using adequate contraception means as assessed by Investigator

at randomisation:

  1. Diagnosed with type 2 DM, as per Investigator discretion
  2. HbA1c (DCCT-standard) must be ≥ 8.0% and ≤12% as evidenced by central lab value
  3. Insulin resistance defined as required daily dose between 0.7-1.8 U/Kg or a maximum of 220 units of insulin per day
  4. On MDI (basal/bolus regimen with long-acting insulin and rapid acting analogs) defined as ≥ 3 injections per day
  5. Ability to comply with technology, according to Investigator's judgment
  6. ≥ 2.5 SMBG per day on average, as reported in Carelink clinical during the run-in phase.
  7. Patients must be willing to undergo all study procedures
  8. Female patients of child-bearing potential must be using adequate contraception means as assessed by Investigator

Exclusion Criteria :

  1. Subject has a history (≥ 2 events) of hypoglycemic seizure or hypoglycemic coma within the last 6 months
  2. Subject is pregnant as assessed by a pregnancy test with central laboratory, or plans to become pregnant during the course of the study
  3. Participation in another interventional clinical study, on-going or completed less than 3 months prior to signature of Patient Informed Consent.
  4. Subject has proliferative retinopathy or sight threatening maculopathy
  5. Subject has

    • an acute coronary syndrome (myocardial infarction or unstable angina) within 12 months OR
    • coronary artery revascularization by bypass surgery or stenting within 3 months OR
    • a transient ischemic attack (TIA) or cerebrovascular accident (CVA) within 3 months OR
    • hospitalization for heart failure within 3 months or current New York Functional Class III or IV OR
    • current 2nd or 3rd degree heart block OR
    • symptomatic ventricular rhythm disturbances OR
    • thromboembolic disease within the last 3 months OR
    • 2nd degree Mobitz type II or 3rd degree heart block
  6. Subject with renal impairment expressed as estimated glomerular filtration rate (eGFR) using the Modification of Diet in Renal Disease (MDRD) formula < 30 ml/min as demonstrated by the screening central laboratory value at the time of enrollment
  7. Subject has taken oral or injectable steroids within the last 30 days
  8. Systolic blood pressure on screening visit is > 180 mmHg
  9. Diastolic blood pressure on screening visit is > 110 mmHg
  10. Any other disease (eg active cancer under treatment) or condition including abnormalities found on the screening tests, that in the opinion of the Investigator, may preclude him/her from participating in the study
  11. Taking any medication prescribed for weight loss
  12. Alcohol or drug abuse, other than nicotine, at the investigator's discretion
  13. Use of a GLP-1 agonist or pramlintide (Symlin)
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01182493

Contact: Sarah Runzis (+41-21) 802-7028 sarah.runzis@medtronic.com

  Hide Study Locations
United States, Georgia
Atlanta Diabetes Associates Recruiting
Atlanta, Georgia, United States, 30318
Principal Investigator: Bruce Bode, Dr.         
United States, New York
Albany Medical College Recruiting
Albany, New York, United States, 12208
Principal Investigator: Elizabeth Nardacci, NP         
SUNY Upstate Medical University Recruiting
Syracuse, New York, United States, 13210
Principal Investigator: Rutgh Weinstock, MD         
City hopital Vienna-Hieting Recruiting
Vienna, Austria, 1130
Principal Investigator: Rudolf Prager, MD         
Canada, Alberta
Clinical Professor Department of Medicine University of Calgary Recruiting
Calgary, Alberta, Canada, T3B 0M3
Principal Investigator: Stuart Ross, Dr.         
Canada, British Columbia
Endocrinologist, 202-301 Columbia Street East Recruiting
New Westminster, British Columbia, Canada, V3L 3W5
Principal Investigator: Anne Priestman, Dr.         
416-1033 Davie St Recruiting
Vancouver, British Columbia, Canada, V6E 1M7
Principal Investigator: Hugh Tildesley, Dr.         
Canada, Newfoundland and Labrador
Health Science Centre Recruiting
St. John's, Newfoundland and Labrador, Canada, A1B 3V6
Principal Investigator: Carol Joyce, Dr.         
Canada, Ontario
LMC Endocrinology Centre Recruiting
Oakville, Ontario, Canada, L6H 3P1
Contact: Ronnie Aronsson, MD         
Principal Investigator: Ronnie Aronsson, MD         
Canadian Centre for Research on Diabetes Recruiting
Smiths' Falls, Ontario, Canada, K7A 4W8
Principal Investigator: Robin Conway, MD         
Toronto General Hsopital Recruiting
Toronto, Ontario, Canada, M5G 2C4
Contact: Bruce Perkins, MD         
Principal Investigator: Bruce A Perkins, MD         
Canada, Quebec
McGill University, McGill Nutrition and Food Science Centre Recruiting
Montreal, Quebec, Canada, H3A 1A1
Principal Investigator: Jean-Francois Yale, Dr.         
Czech Republic
Institute of Neurology and Geriatrics Active, not recruiting
Moravski Beroun, Czech Republic, 79305
CHU Côte de Nacre Recruiting
Caen, France, 14033
Contact: Yves Reznik         
Principal Investigator: Yves Reznik, MD         
CHU - Ste Marguerite Terminated
Marseille, France, 13274
Hopital Lapeyronie Terminated
Montpellier, France, 34295
CHU de Nancy Recruiting
Nancy, France, 54500
Principal Investigator: Bruno Guercy, Prof         
CHU Strasbourg Recruiting
Strasbourg, France, 67091
Principal Investigator: Francois Moreau, Dr.         
CHU Toulouse Rangueil Recruiting
Toulouse, France, 31059
Principal Investigator: Helene Hanaire, Prof.         
Fachklinik Bad Heilbrunn Recruiting
Bad Heilbrunn, Germany, 83670
Principal Investigator: Andreas Liebl, Dr.         
Zentrum für Diabetes und Gefäßerkrankungen Recruiting
Münster, Germany, 48145
Principal Investigator: Ludger Rose, Dr.         
Péterfy Hospital and Emergency Center Diabetes Outpatient Clinic Recruiting
Budapest, Hungary, 1076
Principal Investigator: Győző Kocsis, Dr.         
Soroka University Medical Center Recruiting
Beer-Sheva, Israel, 84105
Principal Investigator: Ilana Harman-Boehm, MD         
Diabetic Clinic Recruiting
Jerusalem, Israel, 93106
Principal Investigator: Muriel Metzger, MD         
Chaim Sheba Medical center Endocrinology unit Recruiting
Tel Hashomer - Ramat Gan, Israel, 5262
Principal Investigator: Ohad Cohen, Prof.         
Assaf- Harofeh Medical Center Recruiting
Zerifin, Israel, 70300
Principal Investigator: Andreas Buchs, MD         
Università degli Studi di Bari - Policlinico Universitario Recruiting
Bari, Italy, 70124
Principal Investigator: Francesco Giorgino, Prof         
Universita di Perugia - Ospedale S.M. Della Misericordia Recruiting
Perugia, Italy, 06132
Principal Investigator: Geremia Bolli, Prof.         
University La Sapienza - Policlinico Recruiting
Roma, Italy, 00161
Principal Investigator: Sebastiano Filetti, Prof.         
Macedonia, The Former Yugoslav Republic of
University Clinic of Endocrinology Recruiting
Skopje, Macedonia, The Former Yugoslav Republic of, 1000
Principal Investigator: Goran Petrovski, Prof.         
IJsselland Ziekenhuis Poli Interne geneeskunde Recruiting
Capelle a/d IJssel, Netherlands, 2906
Principal Investigator: RA Alwani, Dr.         
Maxima Medisch Centrum Recruiting
Eindhoven, Netherlands, 5600
Principal Investigator: Louis Lieverse, Dr.         
Bethesda Diabetes Research Center Recruiting
Hoogeveen, Netherlands, 7900
Principal Investigator: Adriaan Kooy, Dr         
Clinic for Endocrinology, Diabetes and Metabolic Diseases Recruiting
Belgrade, Serbia, 11 000
Principal Investigator: Nebojsa Lalic, Prof.         
South Africa
Centre for Diabetes and Endocrinology Recruiting
Johannesburg, South Africa, 2198
Principal Investigator: Larry Distiller, Prof.         
Dr.Garcjan Podgorski Recruiting
Port Elizabeth, South Africa, 6001
Contact: Garcjan Podgorski, Dr.         
Principal Investigator: Gracjan Podgorski, Dr.         
ICMDM Hospital Clínic i Universitari Recruiting
Barcelona, Spain, 08036
Contact: Ignacio Conget, Dr         
Principal Investigator: Ignacio Conget, MD         
Sponsors and Collaborators
Principal Investigator: Ohad Cohen, MD Chaim Sheba Medical Center, Tel Hashomer, Israel
Principal Investigator: Ignacio Conget, MD ICMDM Hospital Clínic i, Barcelona, Spain
Principal Investigator: Yves Reznic, MD CHU Côte de Nacre, France
Principal Investigator: Ronnie Aronson, MD FRCPC, FACE LMC Endocrinology Centres, Canada
  More Information

No publications provided

Responsible Party: Medtronic
ClinicalTrials.gov Identifier: NCT01182493     History of Changes
Other Study ID Numbers: EUR05 / CEP234
Study First Received: August 11, 2010
Last Updated: April 12, 2013
Health Authority: Austria: Agency for Health and Food Safety
Austria: Ethikkommission
Canada: Ethics Review Committee
Canada: Health Canada
Czech Republic: Ethics Committee
France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
France: Comité consultatif sur le traitement de l'information en matière de recherche dans le domaine de la santé
France: Direction Générale de la Santé
France: Institutional Ethical Committee
France: Agence Nationale de Sécurité du Médicament et des produits de santé
France: The Commission nationale de l’informatique et des libertés
Germany: Ethics Commission
Germany: Federal Institute for Drugs and Medical Devices
Hungary: Institutional Ethics Committee
Hungary: National Institute for Quality and Organizational Development in Healthcare and Medicines
Hungary: Research Ethics Medical Committee
Hungary: Scientific and Medical Research Council Ethics Committee
Israel: Ethics Commission
Israel: Israeli Health Ministry Pharmaceutical Administration
Israel: Ministry of Health
Italy: Ethics Committee
Italy: National Institute of Health
Macedonia: Ethics Committee
Macedonia: Ministry of Health
Netherlands: Independent Ethics Committee
Netherlands: Dutch Health Care Inspectorate
Netherlands: Medical Ethics Review Committee (METC)
Serbia: Ethics Committee
South Africa: Human Research Ethics Committee
South Africa: National Health Research Ethics Council
Spain: Ethics Committee
Spain: Ministry of Health
United States: Institutional Review Board

Keywords provided by Medtronic:
Diabetes Mellitus
pump therapy

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Hypoglycemic Agents
Physiological Effects of Drugs
Pharmacologic Actions

ClinicalTrials.gov processed this record on April 14, 2014